Every cloud has a silver lining: Portugal's loss may be the UK's gain
This article was originally published in SRA
The innovator pharmaceutical industry was disappointed by a recent CJEU ruling relating to supplementary protection certificates in Portugal. However, there could be a positive flip side, writes Mike Snodin.
You may also be interested in...
Just five weeks before the US election, a Medtech Insight analysis shows medical device companies are spending more on Democrat Joe Biden’s campaign than on Republican Donald Trump’s.
Denmark’s Orphazyme has raised more funds to market its lead product, the heat shock protein amplifier, arimoclomol, in the US and Europe, and to evaluate the compound for other lysosomal storage and neurodegenerative disorders.
Pacific Biosciences of California and Aziyo Biologics both acquire new finance chiefs; Illumina hires a new chief marketing officer; WishBone Medical president moves over to take helm at Electromedical Products International; and more.